Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer / Bianchini, G., Kiermaier, A., Bianchi, G.v., Im, Y.h., Pienkowski, T., Liu, M.c., Tseng, L.m., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, L.c., Valagussa, P., Gianni, L.. - In: BREAST CANCER RESEARCH. - ISSN 1465-5411. - (2017).